9-2-5-4　ⓔ文献

  1. Zamponi GW, Striessnig J, et al: The physiology, pathology, and pharmacology of voltage–gated calcium channels and their future therapeutic potential. Pharmacol Rev, 2015; 67: 821–870.

  2. Hayashi K, Homma K, et al: T–type Ca channel blockade as a determinant of kidney protection. Keio J Med, 2010; 59: 84–95.

  3. Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab, 2008; 9: 310–322.

  4. Kobori H, Nangaku M, et al: The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev, 2007; 59: 251–287.

  5. Kobori H, Mori H, et al: Angiotensin II blockade and renal protection. Curr Pharm Des, 2013; 19: 3033–3042.

  6. Choi HK, Soriano LC, et al: Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ, 2012; 344: d8190.

  7. Li EC, Heran BS, et al: Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev, 2014; 8: CD009096.

  8. Blood Pressure Lowering Treatment Trialists’ Collaboration, Turnbull F, Neal B, et al: Blood pressure–dependent and independent effects of agents that inhibit the renin–angiotensin system. J Hypertens, 2007; 25: 951–958. (Erratum in: J Hypertens, 2007; 25: 1524)

  9. Caldeira D, Alarcão J, et al: Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta–analysis. BMJ, 2012; 345: e4260.

  10. Brown NJ, Byiers S, et al: Dipeptidyl peptidase–IV inhibitor use associated with increased risk of ACE inhibitor–associated angioedema. Hypertension, 2009; 54: 516–523.

  11. SPRINT Research Group, Wright JT Jr, et al: A randomized trial of intensive versus standard blood–pressure control. N Engl J Med, 2015; 373: 2103–2116.

  12. Glover M, Clayton J: Thiazide–induced hyponatraemia: epidemiology and clues to pathogenesis. Cardiovasc Ther, 2012; 30: e219–226.

  13. Whelton PK, Carey RM, et al: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension, 2018; 71: e13–e115.

  14. Nishiyama A: Pathophysiological mechanisms of mineralocorticoid receptor–dependent cardiovascular and chronic kidney disease. Hypertens Res, 2019; 42: 293–300.

  15. Ezekowitz JA, McAlister FA: Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J, 2009; 30: 469–477.

  16. Yano Y, Hoshide S, et al: Efficacy of eplerenone added to renin–angiotensin blockade in elderly hypertensive patients: the Jichi–Eplerenone Treatment (JET) study. J Renin Angiotensin Aldosterone Syst, 2011; 12: 340–347.

  17. Parving HH, Persson F, et al: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med, 2008; 358: 2433–2446.

  18. Parving HH, Brenner BM, et al: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med, 2012; 367: 2204–2213.

  19. Kario K, Matsui Y, et al: Japan Morning Surge–1 (JMS–1) Study Group. An alpha-adrenergic blocker titrated by self–measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study. J Hypertens, 2008; 26: 1257–1265.

  20. Hirota T, Schwartz S, et al: Alpha-2 agonists for attention–deficit/hyperactivity disorder in youth: a systematic review and meta–analysis of monotherapy and add–on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry, 2014; 53: 153–173.